Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Plasma cell 5Thoracic 2Other hematologic neoplasm 2Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hyaluronoglucosaminidase × Thoracic × 1 year × Clear all
NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

University of Southern California

Phase 2 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡